Transcend Therapeutics
Stephanie comes to Transcend from Axsome Therapeutics. In her previous role, Stephanie worked on clinical trials for Major Depressive Disorder, Migraine, ADHD, and Narcolepsy. Studying neuroscience at the University of Vermont catalyzed her interest in neuropsychiatric disease and the pharmaceutical industry.
Transcend Therapeutics
1 followers
Transcend Therapeutics is a clinical-stage, neuroscience-focused company developing next-generation psychoactive medicines for neuropsychiatric disease. Transcend develops medicines that are accessible to a larger percentage of patients in need, specifically the tens of millions of patients who already take psychotropic medication. We have real-world data showing that our lead product provided significant benefit to >85% of patients with PTSD and depression. We have already advanced our lead compound into an approved Phase II study in PTSD, with plans to expand into depression and other indications.